On Oct 29, major Wall Street analysts update their ratings for $Edwards Lifesciences (EW.US)$, with price targets ranging from $70 to $90.
J.P. Morgan analyst Robbie Marcus maintains with a hold rating.
BofA Securities analyst Travis Steed maintains with a hold rating, and maintains the target price at $75.
Citi analyst Joanne Wuensch maintains with a buy rating, and adjusts the target price from $77 to $81.
Barclays analyst Matt Miksic maintains with a buy rating, and maintains the target price at $85.
Wells Fargo analyst Larry Biegelsen maintains with a buy rating, and maintains the target price at $80.
Furthermore, according to the comprehensive report, the opinions of $Edwards Lifesciences (EW.US)$'s main analysts recently are as follows:
Edwards Lifesciences delivered a robust performance, surpassing sales and earnings expectations. The outlook for Q4 and the strategic vision set for 2025 are likely to sustain the stock's upward trajectory.
Following the Q3 report, there is a belief that it will require several more quarters for Edwards Lifesciences to demonstrate to investors that it has established a baseline for the performance of its TAVR franchise.
Expectations were modest prior to the release of the third-quarter results, and the subsequent discussion for the fourth quarter and fiscal year 2025 did not strongly indicate that risks were already priced in. Although the deceleration in fourth-quarter TAVR trends appears to be influenced by certain one-time factors, it remains challenging to definitively argue that TAVR growth will not continue to slow down in fiscal year 2025.
Here are the latest investment ratings and price targets for $Edwards Lifesciences (EW.US)$ from 10 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月29日，多家華爾街大行更新了$愛德華生命科學 (EW.US)$的評級，目標價介於70美元至90美元。
摩根大通分析師Robbie Marcus維持持有評級。
美銀證券分析師Travis Steed維持持有評級，維持目標價75美元。
花旗分析師Joanne Wuensch維持買入評級，並將目標價從77美元上調至81美元。
巴克萊銀行分析師Matt Miksic維持買入評級，維持目標價85美元。
富國集團分析師Larry Biegelsen維持買入評級，維持目標價80美元。
此外，綜合報道，$愛德華生命科學 (EW.US)$近期主要分析師觀點如下：
愛德華生命科學的表現強勁，超過了銷售和盈利預期。對於第四季度的展望以及制定的2025年戰略願景可能會繼續支撐股票的上升軌跡。
根據第三季度報告，人們認爲愛德華生命科學需要幾個季度的時間向投資者證明其TAVR業務績效已經確立基線。
在第三季度業績公佈前，預期並不算高，而隨後對第四季度和2025財年的討論並沒有強烈表明風險已經被充分定價。儘管第四季度TAVR趨勢的減速似乎受到某些一次性因素的影響，但仍然很難明確地認爲TAVR的增長不會在2025財年繼續放緩。
以下爲今日10位分析師對$愛德華生命科學 (EW.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
